Can We Intercept Cancer? A New Frontier in Cancer Research Penn Medicine News News | Feb 28, 2023 Can we stop cancer before it starts? That’s part of the goal of cancer interception, which involves “catching” cancer cells as they begin to develop into pre-cancers or very early cancers, and halt or reverse that process. Latest News Blackstone President Jonathan Gray Donates $25 Million To Tackle Deadly Breast Cancer Gene Forbes News | July 2019 Basser Center founders Mindy and Jon Gray have announced a further $25 million in funding for BRCA-related research. The grants will be split among seven research teams across the globe. Deputy Director of Penn’s Abramson Cancer Center Receives $3 Million Grant from The Gray Foundation Penn Medicine News News | July 2019 Katherine L. Nathanson, MD, has been awarded a $3 million research grant from the Gray Foundation, which will support Nathanson and her team as they study new approaches to understanding immune function both in healthy BRCA mutation carriers and BRCA-related cancers. Women proudly model bikinis after body-changing battles New York Post News | July 2019 Basser Young Leadership co-chair Erika Stallings is featured in a body awareness piece from the New York Post, where she discusses life after a preventive mastectomy. 16 Things Doctors Wish You Knew About Breast Cancer Genetic Testing Reader's Digest News | June 2019 Reader's Digest shares a helpful list of what doctors wish you knew about breast cancer and genetic testing (including a Basser Center mention). How Alejandra Campoverdi Outwitted Breast Cancer While Helping Women Save Their Own Lives People En Espanol News | June 2019 Alejandra Campoverdi shares her story with People En Espanol and discusses her BRCA2 mutation, her recent preventative mastectomy, and her new collaboration with the Basser Center: LATINO & BRCA, the first BRCA-related awareness campaign focused on the Latino community. How Should Patients and Providers Interpret the US Food and Drug Administration’s Regulatory Language for Direct-to-Consumer Genetic Tests? Journal of Clinical Oncology News | June 2019 In the Journal of Clinical Oncology, Basser Executive Director Susan Domchek, MD, discusses at-home genetic testing and the FDA’s regulatory language, which might confuse not only consumers, but also medical providers who are asked to interpret results and make clinical recommendations. Trial Highlights Complexities of Targeted Therapy for Pancreatic Cancer National Cancer Institute News | June 2019 Susan Domchek, MD, executive director of the Basser Center, discusses the state of research showing PARP inhibitors can be effective for pancreatic patients with BRCA mutations. Doctors Outline New Discoveries in the Fight to Cure Ovarian Cancer Main Line Times News | May 2019 Mainline Media News profiles the work of Dr. Ronny Drapkin, the Basser Center's Director of Gynecologic Cancer Research. How to Quell a Cytokine Storm: International Team Finds New Ways to Dampen an Overactive Immune System Penn Medicine News News | May 2019 Researchers at Penn Medicine and University of Leeds, co-led by the Basser's Roger Greenberg, MD, PhD, have deciphered the structure of a multipart, molecular complex that is also responsible for regulating the immune system and have found new molecular targets for fighting autoimmunity. I Had a Preventive Mastectomy—Then Found Out I Already Had Breast Cancer Yahoo Lifestyle News | May 2019 Alejandra Campoverdi, who has partnered with the Basser Center for our LATINX & BRCA initiative, speaks about her recent preventative mastectomy. Penn Research Provides Insight into Genetic Link to Potential Treatment Response Among BRCA1/2 Breast Cancer Patients Penn Medicine News News | May 2019 New findings from Penn Medicine researchers, including the study’s senior author, Basser’s Katherine L. Nathanson, MD, provide clues about immune response of tumors in patients with BRCA-related breast cancers. The research could shape treatment strategies and clinical trials. Pancreatic cancer treatments show promise in studies, Penn reports Philadelphia Inquirer News | April 2019 The Philadelphia Inquirer highlights a Penn Medicine and Basser Center study, led by Kim Reiss Binder, MD, an assistant professor of Hematology-Oncology, which examines PARP inhibitors in patients with BRCA mutations. Ask the Expert: Senior Genetic Counselor, Dana Clark, Explains BRCA Gene Mutations Health Central News | March 2019 Basser Center genetic counselor Dana Farengo Clark, MS, LCGC, helps to explain BRCA mutations and the process of genetic testing and counseling. Taking the Uncertainty Out of Interpreting BRCA Variants Journal of the American Medical Association News | March 2019 Basser Executive Director Susan Domchek, MD, discusses a new resource with JAMA that may help guide clinical decision-making related to BRCA genetic mutations. Lead Researcher Discusses Durvalumab/Olaparib Combo in Breast Cancer OncLive News | January 2019 Basser Center Executive Director Susan Domchek, MD, discusses the role of specific PARP inhibitors in an ongoing breast cancer trial. Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers Journal of the American Medical Association News | December 2018 Basser Center Executive Director Susan Domchek, MD, discusses the complex issue of risk-reducing mastectomy in BRCA mutation carriers in an editorial for the Journal of the American Medical Association. Blackstone COO Jonathan Gray On Giving To Education, Cancer Research Forbes News | October 2018 Basser Center founders Mindy and Jon Gray have a well-deserved spot on Forbes' annual list of top 50 philanthropists. "In total, Gray has given over $120 million in his lifetime, primarily to cancer research and health and education in New York City." Evening of Storytelling Speaks to Future of Cancer Research Cure Magazine News | October 2018 The Basser Center's Young Leadership Council recently hosted a storytelling event featuring personal stories from three individuals touched by BRCA mutations, which all spoke to the promising future that research will provide for future patients and the newly BRCA-positive population. Pagination First page« First Previous page‹‹ … Page2 Page3 Page4 Page5 Page6 Current page7 Page8 Page9 Page10 Next page›› Last pageLast »
Can We Intercept Cancer? A New Frontier in Cancer Research Penn Medicine News News | Feb 28, 2023 Can we stop cancer before it starts? That’s part of the goal of cancer interception, which involves “catching” cancer cells as they begin to develop into pre-cancers or very early cancers, and halt or reverse that process.
Blackstone President Jonathan Gray Donates $25 Million To Tackle Deadly Breast Cancer Gene Forbes News | July 2019 Basser Center founders Mindy and Jon Gray have announced a further $25 million in funding for BRCA-related research. The grants will be split among seven research teams across the globe.
Deputy Director of Penn’s Abramson Cancer Center Receives $3 Million Grant from The Gray Foundation Penn Medicine News News | July 2019 Katherine L. Nathanson, MD, has been awarded a $3 million research grant from the Gray Foundation, which will support Nathanson and her team as they study new approaches to understanding immune function both in healthy BRCA mutation carriers and BRCA-related cancers.
Women proudly model bikinis after body-changing battles New York Post News | July 2019 Basser Young Leadership co-chair Erika Stallings is featured in a body awareness piece from the New York Post, where she discusses life after a preventive mastectomy.
16 Things Doctors Wish You Knew About Breast Cancer Genetic Testing Reader's Digest News | June 2019 Reader's Digest shares a helpful list of what doctors wish you knew about breast cancer and genetic testing (including a Basser Center mention).
How Alejandra Campoverdi Outwitted Breast Cancer While Helping Women Save Their Own Lives People En Espanol News | June 2019 Alejandra Campoverdi shares her story with People En Espanol and discusses her BRCA2 mutation, her recent preventative mastectomy, and her new collaboration with the Basser Center: LATINO & BRCA, the first BRCA-related awareness campaign focused on the Latino community.
How Should Patients and Providers Interpret the US Food and Drug Administration’s Regulatory Language for Direct-to-Consumer Genetic Tests? Journal of Clinical Oncology News | June 2019 In the Journal of Clinical Oncology, Basser Executive Director Susan Domchek, MD, discusses at-home genetic testing and the FDA’s regulatory language, which might confuse not only consumers, but also medical providers who are asked to interpret results and make clinical recommendations.
Trial Highlights Complexities of Targeted Therapy for Pancreatic Cancer National Cancer Institute News | June 2019 Susan Domchek, MD, executive director of the Basser Center, discusses the state of research showing PARP inhibitors can be effective for pancreatic patients with BRCA mutations.
Doctors Outline New Discoveries in the Fight to Cure Ovarian Cancer Main Line Times News | May 2019 Mainline Media News profiles the work of Dr. Ronny Drapkin, the Basser Center's Director of Gynecologic Cancer Research.
How to Quell a Cytokine Storm: International Team Finds New Ways to Dampen an Overactive Immune System Penn Medicine News News | May 2019 Researchers at Penn Medicine and University of Leeds, co-led by the Basser's Roger Greenberg, MD, PhD, have deciphered the structure of a multipart, molecular complex that is also responsible for regulating the immune system and have found new molecular targets for fighting autoimmunity.
I Had a Preventive Mastectomy—Then Found Out I Already Had Breast Cancer Yahoo Lifestyle News | May 2019 Alejandra Campoverdi, who has partnered with the Basser Center for our LATINX & BRCA initiative, speaks about her recent preventative mastectomy.
Penn Research Provides Insight into Genetic Link to Potential Treatment Response Among BRCA1/2 Breast Cancer Patients Penn Medicine News News | May 2019 New findings from Penn Medicine researchers, including the study’s senior author, Basser’s Katherine L. Nathanson, MD, provide clues about immune response of tumors in patients with BRCA-related breast cancers. The research could shape treatment strategies and clinical trials.
Pancreatic cancer treatments show promise in studies, Penn reports Philadelphia Inquirer News | April 2019 The Philadelphia Inquirer highlights a Penn Medicine and Basser Center study, led by Kim Reiss Binder, MD, an assistant professor of Hematology-Oncology, which examines PARP inhibitors in patients with BRCA mutations.
Ask the Expert: Senior Genetic Counselor, Dana Clark, Explains BRCA Gene Mutations Health Central News | March 2019 Basser Center genetic counselor Dana Farengo Clark, MS, LCGC, helps to explain BRCA mutations and the process of genetic testing and counseling.
Taking the Uncertainty Out of Interpreting BRCA Variants Journal of the American Medical Association News | March 2019 Basser Executive Director Susan Domchek, MD, discusses a new resource with JAMA that may help guide clinical decision-making related to BRCA genetic mutations.
Lead Researcher Discusses Durvalumab/Olaparib Combo in Breast Cancer OncLive News | January 2019 Basser Center Executive Director Susan Domchek, MD, discusses the role of specific PARP inhibitors in an ongoing breast cancer trial.
Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers Journal of the American Medical Association News | December 2018 Basser Center Executive Director Susan Domchek, MD, discusses the complex issue of risk-reducing mastectomy in BRCA mutation carriers in an editorial for the Journal of the American Medical Association.
Blackstone COO Jonathan Gray On Giving To Education, Cancer Research Forbes News | October 2018 Basser Center founders Mindy and Jon Gray have a well-deserved spot on Forbes' annual list of top 50 philanthropists. "In total, Gray has given over $120 million in his lifetime, primarily to cancer research and health and education in New York City."
Evening of Storytelling Speaks to Future of Cancer Research Cure Magazine News | October 2018 The Basser Center's Young Leadership Council recently hosted a storytelling event featuring personal stories from three individuals touched by BRCA mutations, which all spoke to the promising future that research will provide for future patients and the newly BRCA-positive population.
